TOMANIN, ROSELLA
 Distribuzione geografica
Continente #
NA - Nord America 2.856
AS - Asia 1.389
EU - Europa 853
SA - Sud America 287
AF - Africa 276
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 11
Totale 5.708
Nazione #
US - Stati Uniti d'America 2.679
SG - Singapore 532
CN - Cina 271
BR - Brasile 186
HK - Hong Kong 145
IT - Italia 119
VN - Vietnam 110
DE - Germania 108
SE - Svezia 87
FI - Finlandia 74
PL - Polonia 49
GB - Regno Unito 42
NL - Olanda 37
FR - Francia 35
IN - India 35
JP - Giappone 28
UA - Ucraina 26
RU - Federazione Russa 24
AR - Argentina 21
CA - Canada 19
MX - Messico 18
AT - Austria 17
EC - Ecuador 17
TR - Turchia 17
ID - Indonesia 16
JO - Giordania 16
ES - Italia 15
PA - Panama 15
IE - Irlanda 14
JM - Giamaica 14
ZA - Sudafrica 14
CI - Costa d'Avorio 13
KR - Corea 13
PT - Portogallo 13
BJ - Benin 12
CH - Svizzera 12
CZ - Repubblica Ceca 12
GA - Gabon 12
GM - Gambi 12
IS - Islanda 12
MA - Marocco 12
IL - Israele 11
IQ - Iraq 11
SN - Senegal 11
SO - Somalia 11
TT - Trinidad e Tobago 11
CU - Cuba 10
HU - Ungheria 10
IR - Iran 10
LA - Repubblica Popolare Democratica del Laos 10
MD - Moldavia 10
MY - Malesia 10
PH - Filippine 10
PS - Palestinian Territory 10
PY - Paraguay 10
SK - Slovacchia (Repubblica Slovacca) 10
AL - Albania 9
AU - Australia 9
BY - Bielorussia 9
CL - Cile 9
CR - Costa Rica 9
DZ - Algeria 9
HN - Honduras 9
HR - Croazia 9
ME - Montenegro 9
MZ - Mozambico 9
NI - Nicaragua 9
NO - Norvegia 9
SA - Arabia Saudita 9
SI - Slovenia 9
AM - Armenia 8
AO - Angola 8
CO - Colombia 8
EG - Egitto 8
GE - Georgia 8
LV - Lettonia 8
PE - Perù 8
SD - Sudan 8
TW - Taiwan 8
UZ - Uzbekistan 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
BA - Bosnia-Erzegovina 7
BD - Bangladesh 7
BS - Bahamas 7
BW - Botswana 7
GF - Guiana Francese 7
GH - Ghana 7
HT - Haiti 7
LB - Libano 7
LC - Santa Lucia 7
LU - Lussemburgo 7
MK - Macedonia 7
ML - Mali 7
MR - Mauritania 7
NZ - Nuova Zelanda 7
PK - Pakistan 7
RS - Serbia 7
TZ - Tanzania 7
Totale 5.425
Città #
Fairfield 316
Ashburn 310
Singapore 288
Houston 270
Chandler 209
Ann Arbor 186
Woodbridge 171
Hong Kong 138
Seattle 131
Wilmington 123
Cambridge 120
Beijing 90
Santa Clara 59
Munich 55
Boardman 51
Jacksonville 50
Padova 49
Bytom 43
Ho Chi Minh City 40
Los Angeles 39
Princeton 38
Helsinki 32
New York 31
San Diego 29
Des Moines 25
Medford 24
Tokyo 21
Dong Ket 20
Nanjing 19
Hanoi 18
Amman 16
Chicago 16
São Paulo 16
Turku 15
Panama City 14
Abidjan 13
Nuremberg 13
Buffalo 12
Cotonou 12
Dakar 11
Kingston 11
Libreville 11
Rio de Janeiro 10
Vienna 10
Vientiane 10
Falls Church 9
Frankfurt am Main 9
Havana 9
London 9
Managua 9
Poplar 9
San José 9
Dublin 8
Hefei 8
Kuala Lumpur 8
Mexico City 8
Phoenix 8
Reykjavik 8
Tbilisi 8
Yerevan 8
Accra 7
Amsterdam 7
Apia 7
Baku 7
Belo Horizonte 7
Castries 7
Council Bluffs 7
Falkenstein 7
Hargeisa 7
Kampala 7
Khartoum 7
Lusaka 7
Minsk 7
Nassau 7
Riga 7
Roxbury 7
Shenyang 7
Toronto 7
Auckland 6
Bishkek 6
Boston 6
Bridgetown 6
Chisinau 6
Conakry 6
Dar es Salaam 6
Gaborone 6
Jakarta 6
Johannesburg 6
Lisbon 6
Luanda 6
Milan 6
Nouakchott 6
Noumea 6
Pune 6
Willemstad 6
Bamako 5
Brissago Valtravaglia 5
Budapest 5
Changsha 5
Da Nang 5
Totale 3.565
Nome #
Perturbations in cell signaling elicit early cardiac defects in mucopolysaccharidosis type II 267
High transduction efficiency of human amniotic fluid stem cells mediated by adenovirus vectors 248
QueryOR: a comprehensive web platform for genetic variant analysis and prioritization 237
Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment 220
A Hunter Patient with a Severe Phenotype Reveals Two Large Deletions and Two Duplications Extending 1.2 Mb Distally to IDS Locus 209
Brain RNA-seq profiling of the mucopolysaccharidosis type II mouse model 208
Gene therapy of Hunter syndrome: Evaluation of the efficiency of muscle electro genetransfer for the production and release of recombinant iduronate-2-sulfatase (IDS) 196
RNA-seq Transcriptome Profiling Of Primary Hunter Cells Following Treatment With Recombinant IDS As A First Step For Identification Of ERT Efficacy Markers 193
FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII). 192
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders 189
A column-switching HPLC-MS/MS method for mucopolysaccharidosis type I analysis in a multiplex assay for the simultaneous newborn screening of six lysosomal storage disorders. 183
A rapid testing procedure for Fabry disease: alpha-galadosidase A assay in dried blood spots 182
Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved 181
Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years 171
Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts 170
Targeting brain disease in MPSII: Preclinical evaluation of IDS-loaded PLGA nanoparticles 167
Setup and Validation of a Targeted Next-Generation Sequencing Approach for the Diagnosis of Lysosomal Storage Disorders 152
Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction 142
Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study 142
Drosophila d-idua reduction mimics mucopolysaccharidosis type i disease-related phenotypes 140
Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. 138
Exploiting the potential of drosophila models in lysosomal storage disorders: Pathological mechanisms and drug discovery 136
Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. 131
A novel CRISPR/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes 130
BBB Crossing in Lysosomal Storage Disorders: A Nanoparticle-Based Approach 129
Mucopolysaccharidosis type II: One hundred years of research, diagnosis, and treatment 125
Antiretroviral activity of furocoumarins plus UVA light detected by a replication-defective retrovirus 119
Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro 115
Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model 114
Corrigendum: FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII) [Human Molecular Genetics, 27, 13, (2018) (2262-2275)] DOI: 10.1093/hmg/ddy131 107
Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy 101
Rapid diagnostic testing procedures for lysosomal storage disorders: alpha-glucosidase and beta-galactosidase assays on dried blood spots 99
Early axon guidance and synapse maturation defects in a zebrafish model of Mucopolysaccharidosis type II 95
Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study 92
Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment 91
Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans-A Diagnostic Prediction Model 87
Evaluation of the antiviral activity of psoralens. G. Miolo, R. Tomanin, A. De Rossi, F. Dall'Acqua, F. Zacchello, M. Scarpa. 84
A replication defective retrovirus model for the identification of psoralens with antiretroviral activity. 80
Totale 5.762
Categoria #
all - tutte 18.570
article - articoli 17.763
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.333


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021318 0 0 0 0 15 31 11 31 53 105 33 39
2021/2022477 22 37 57 30 64 36 30 34 36 9 41 81
2022/2023414 59 40 9 58 45 66 0 41 56 8 27 5
2023/2024243 11 36 30 22 17 36 20 15 4 6 30 16
2024/20251.101 13 61 57 54 108 48 67 84 88 42 183 296
2025/20262.031 196 310 526 596 403 0 0 0 0 0 0 0
Totale 5.762